toxylact: a07ba chargoal preparations

The first professional lActological database in the word

Charcoal preparations (ATC A07BA) are intestinal adsorbents based on activated charcoal, used mainly for acute poisoning and, at lower doses, for symptomatic management of diarrhea, with negligible systemic absorption and a very low theoretical risk during breastfeeding.atcddd.fhi+3

ATC A07BA classification

ATC subgroup A07BA comprises “Charcoal preparations” within the wider class A07B intestinal adsorbents. These medicines are classified under the alimentary tract group A and are distinguished from bismuth and other mineral adsorbents by their carbon-based, highly porous structure.atcddd.fhi+3

Pharmacology and mechanism

Activated charcoal has an exceptionally large internal surface area that allows non‑specific adsorption of many drugs, phytotoxins, and chemicals within the gastrointestinal lumen. By binding these substances, charcoal reduces their absorption from the gut and promotes their elimination in the feces, thereby limiting systemic toxicity.ncbi.nlm.nih+4

Therapeutic indications

Clinically, A07BA charcoal preparations are primarily used for gastrointestinal decontamination after ingestion of potentially toxic doses of drugs or other poisons, ideally within one hour of exposure. At lower doses, some oral charcoal products are also used as intestinal adsorbents for common diarrhea, with defined daily doses in the ATC/DDD system based on this indication.medicalguidelines.msf+6

Dosage and administration (context for risk)

For acute poisoning, typical single doses are around 1 g/kg (for example 50 g in adults) given as a suspension; repeated smaller doses may be used over 24 hours in selected cases. For common diarrhea, considerably lower doses are used, resulting in much lower total charcoal exposure and reinforcing the expectation of minimal systemic and milk transfer.medicalguidelines.msf+3

Pharmacokinetics relevant to lactation

Activated charcoal is not absorbed from the intact gastrointestinal tract; it remains confined to the lumen and is excreted unchanged in the feces. Because systemic bioavailability is essentially zero, passage of intact charcoal particles into human milk is not expected and would be, at most, negligible from a toxicological perspective.ncbi.nlm.nih+3

Maternal safety considerations

Common adverse effects in adults include nausea, vomiting, constipation, and, rarely, aspiration if administered to patients with impaired airway reflexes. Contraindications include unprotected airway, risk of gastrointestinal perforation or obstruction, and situations where activated charcoal does not effectively adsorb the ingested substance (for example, caustics, iron, lithium, alcohols), which affects clinical utility but not specifically lactation safety.ncbi.nlm.nih+3

Lactation safety profile

Given the lack of gastrointestinal absorption, charcoal preparations used orally in usual therapeutic doses are considered compatible with breastfeeding, with no expected clinically relevant exposure for the breastfed infant via milk. The main lactation‑related concern is the underlying maternal condition (for example, serious poisoning requiring intensive care) rather than the charcoal itself, and breastfeeding decisions should be guided by maternal stability and the nature of the toxin.ncbi.nlm.nih+3

Potential effects on the breastfed infant

Direct toxic effects in the infant from maternal oral charcoal are not anticipated because transfer into milk should be negligible and charcoal itself is inert when not ingested. If the mother’s poisoning involves agents that can pass into breast milk, separate risk assessment of the specific toxin is necessary, and temporary interruption of breastfeeding may be required for those substances, independently of charcoal administration.ncbi.nlm.nih+3

Practical use in breastfeeding women

For breastfeeding women receiving charcoal after accidental poisoning, a case‑by‑case assessment should weigh the risk of the ingested substance, the timing of exposure, and alternative feeding options; charcoal per se rarely necessitates interruption of breastfeeding. When low‑dose charcoal is used as an intestinal adsorbent for mild, self‑limited diarrhea, it is generally acceptable to continue breastfeeding without special dose‑timing measures, while maintaining adequate maternal hydration and monitoring the infant for signs of infectious diarrhea.atcddd.fhi+3

Risk–benefit considerations

In the context of emergency toxicology, the substantial benefit of activated charcoal in reducing systemic absorption of many poisons clearly outweighs its minimal theoretical risk during lactation. For over‑the‑counter use in diarrhea, the favorable safety profile, lack of absorption, and absence of expected milk transfer support its classification as a low‑risk option in breastfeeding, provided that prolonged or unnecessary use is avoided and that the cause of diarrhea is correctly evaluated.atcddd.fhi+7


Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.